The Jackson Laboratory

Past Presenters

Click on each presenter to read full biography

Rick Altinger
arrow

Rick Altinger

CEO, Glooko
close
-
Mr. Altinger serves as Glooko’s first CEO, and brings over 15 years of industry experience in healthcare information technologies. While an executive at Intuit Health, Mr. Altinger helped launch the healthcare division’s provider services and drove Intuit’s acquisition of Medfusion in 2010. He also spearheaded Intuit Health’s growth as the leading supplier of patient-provider communication and patient portal services. His technical knowledge and expertise is central to Glooko’s diabetes healthcare platform and its goal of allowing anyone to monitor blood glucose levels regardless of meter, pump, CGM or mobile device type
Bonnie Anderson
arrow

Bonnie Anderson

President and CEO, Veracyte
close
-
President and CEO of Veracyte, a molecular diagnostics company that is pioneering the field of molecular cytology. Her career spans nearly 30 years in regulated diagnostics and life science markets. Under Ms. Anderson’s leadership, the company has achieved significant commercialization milestones since its formation as Veracyte in 2008, becoming a public company in 2013. These include the launch of its first product, the Afirma® Thyroid FNA Analysis, which centers on a genomic test designed to resolve ambiguity in thyroid nodule diagnosis. Backed by multiple, peer-reviewed, published studies and included in leading medical guidelines, Afirma is changing how physicians evaluate thyroid nodules – helping thousands of patients avoid unnecessary surgery and reducing healthcare costs. In 2011, Veracyte was named to The Wall Street Journal’s “The Next Big Thing” list of the top 50 venture-backed companies and in 2013, the company was honored with FierceMedicalDevice’s “Fierce 15” award. Prior to Veracyte, Ms. Anderson provided strategic consulting services to venture capital firms and early-stage businesses following 18 years in leadership positions at Beckman Coulter. She currently serves as a member of the Board of Trustees of Keck Graduate Institute of Applied Life Sciences. She graduated from Indiana University of Pennsylvania with a Bachelors of Science degree in Medical Technology. Ms. Anderson has received numerous awards during her career, including being named in 2013 as one of the “Best Bay Area Life Sciences CEOs” by the San Francisco Business Times.
Jean-François Beaulé
arrow

Jean-François Beaulé

Executive Vice President, UnitedHealth Group
close
-
As executive vice president, Health Plan Design and Innovation, Mr. Beaulé leads the strategy for health plan engagement and design for UnitedHealth Group. Mr. Beaulé joined the company in 2006 as chief actuary of National Accounts, and currently leads innovations in the areas of consumer decision making in health and behavioral economics. Most recently, he developed and launched a standardized health score to promote individual health ownership. Earlier positions included those with Towers Perrin in Montreal and Cigna. He holds a bachelor's degree in Actuarial Sciences from Laval University, Québec City and is a Fellow of the Society of Actuaries.
Stephen Bloch
arrow

Stephen Bloch

General Partner, Canaan Partners
close
-
Stephen Bloch is a general partner, Canaan Partners, and currently serves on the boards of companies in digital health, biopharma, medical devices and diagnostics. Previously, Mr. Bloch founded multiple start-ups, including Radiology Management Sciences, where he was CEO for six years. He helped start OmniSonics Medical Technologies and co-founded TeleRad. He was a Ewing Marion Kauffman Fellow. He obtained his A.B. from Dartmouth College, his M.A. in the history of science and public policy from Harvard, and his M.D. from the University of Rochester. He trained in medicine at Massachusetts General Hospital/Harvard Medical School and Lenox Hill Hospital/Cornell Medical School.
William C. Bonfield M.D., M.P.H.
arrow

William C. Bonfield M.D., M.P.H.

Chief Medical Officer, Optum Behavioral Solutions
close
-
Dr, Bonfield oversees the development of clinical strategy, including clinical vision. He supervises Quality Management, Consumer Affairs, and Clinical Policy and Training. Dr. Bonfield has 43 years of experience in health care, 24 years in clinical practice and provider administration and 19 years in managed care. Before coming to Optum, he served as Chief Medical Officer of the Maricopa County Regional Behavioral Health Authority, the largest Medicaid behavioral health carve out in the country. In this position, he managed the Medical Affairs Department, Pharmacy Department, Medical and Nursing Staff, and the Quality Management Department.Prior to this role, Dr. Bonfield held senior leadership positions in managed care organizations and mental healthcare facilities and delivery systems. He also maintained a private clinical and consulting practice and served as a management resource to health care providers focusing on program design, professional staff relations, physician recruitment, and quality improvement.
Peter Bowers, M.D.
arrow

Peter Bowers, M.D.

Senior Clinical Officer , Anthem Blue Cross and Blue Shield in Connecticut
close
-
Dr. Peter Bowers is responsible for clinical affairs at Anthem Blue Cross and Blue Shield in Connecticut. He is also responsible for development and execution of medical management, cost of quality care and clinical support for sales in the Connecticut marketplace. Additionally, he has served as Medical Director for Anthem National Accounts and Anthem’s Payment Innovation which created novel value-based models of care delivery and transformation. He joined Anthem Blue Cross and Blue Shield in 2006 from the faculty of the Yale University School of Medicine as a Pediatric Cardiologist where he was active in teaching, clinical practice and biomedical research. He directed the fellowship training program in pediatric cardiology and won the pediatric resident teaching award in addition to an active clinical practice in both the outpatient and inpatient settings. With continuous funding from the National Institute of Health and the Howard Hughes Medical Institute, he investigated embryonic cardiovascular development and identified genetic causes of SIDS and congenital heart disease. Widely published, he has received awards from the Society of Pediatric Research, the American Academy of Pediatrics, the American College of Cardiology and the American Heart Association. A native of Connecticut, Dr. Bowers is a cum laude graduate of Colby College and the University of Connecticut School of Medicine. His post graduate medical training in pediatrics is from the University of Rochester and his fellowship training in pediatric cardiology and human molecular genetics is from Yale University. He lives in Guilford, CT with his wife, an obstetrician/ gynecologist and two daughters.
Andrea Branch. Ph.D.
arrow

Andrea Branch. Ph.D.

Professor Medicine, Liver Diseases, Associate Professor Surgery, Icahn School of Medicine at Mount Sinai
close
-
Dr. Branch is a professor of Medicine at the Icahn School of Medicine at Mount Sinai. She received a B.S. from the University of Michigan (Ann Arbor), an M.S. from the University of California (Irvine), and a Ph.D. from The Rockefeller University (New York). She has advanced training in molecular virology and addictive diseases research. She directs a translational research laboratory and also conducts clinical trials. Her primary research focus is on hepatitis C virus (HCV) infection and other chronic disease conditions that have a major strong inflammatory component.
Simon Budman, Ph.D
arrow

Simon Budman, Ph.D

Founder & CEO, Inflexxion
close
-
Dr. Budman has lectured worldwide and is an expert on data driven health quality improvement. Over the past 15 years, he has worked in the areas of behavioral healthcare, substance abuse, pain medicine and prescription opioid abuse. He has authored over 100 articles and books on behavioral healthcare and substance abuse. He has also been on over 20 NIH grants. He recently has been focused on ways to organize social media data and use it to measure product safety and abuse. Inflexxion’s SaaS software solutions are used in behavioral health, substance abuse and pain care settings nationwide.
Siobhan Bulfin
arrow

Siobhan Bulfin

CEO, Melon Health
close
-
Ms. Bulfin has over 15 years’ experience in social marketing and behavior change, and five years’ experience in applied game design. Her passion lies in empowering people to take control of their health through patient engagement – leveraging peer support, tracking and personalized, contextual interventions. She founded Melon Health after her sister went through breast cancer and Ms. Bulfin saw what was missing. Her mission is to make health care, everywhere care.
Tim Davenport
arrow

Tim Davenport

CEO, Consumable Science
close
-
Mr. Davenport has been involved in innovative and disruptive healthcare companies for the past decade. He served as President of Revolution Health where he led the development of a broad range of innovative offerings of health content, tools and wellness solutions. Recently, Davenport was the CEO of Sermo, a disruptive startup that grew to be the #1 social network for doctors in the U.S. Previously, Davenport was CEO of several technology companies including Best Software where he lead their successful IPO. He has served on the boards or advised: Diagnotes (present), Serena Software, Scraplog, Softrax, Yobongo, Everest Software. He began his career as an economist, then moved into the software industry, taking on senior product management roles leading to his promotion to General Manager of a division of Lotus Software.Tim earned his M.B.A from Harvard Business School and B.A. from Harvard College in Economics. He was also quarterback of the Harvard Football team.
Peter DeVault
arrow

Peter DeVault

Vice President, Epic
close
-
Mr. DeVault came to Epic in the mid-‘90s with a background in science. During his tenure, he has implemented Epic’s Electronic Health Record System at some of the country’s largest healthcare organizations, helped design Epic’s oncology module, and championed the research missions and interoperability goals of all its customers. He has taken on many national leadership roles with organizations including HL7, CCHIT, the EHR Association, ONC’s Standards and Interoperability Framework, and the Sequoia Project. He studies trends in world health and social care and helps international organizations to be successful users of the EHR and learn from each other.
Anthony B. Evnin, Ph.D.
arrow

Anthony B. Evnin, Ph.D.

Partner, Venrock
close
-
Dr. Evnin is a partner at Venrock, a venture capital firm, and on the Board of Directors of AVEO Pharmaceuticals, Infinity Pharmaceuticals, Juno Therapeutics and Constellation Pharmaceuticals. He is a trustee of The Rockefeller University and The Jackson Laboratory; member of the Boards of Overseers and Managers of Memorial Sloan-Kettering Cancer Center and of the Board of Directors of the Albert and Mary Lasker Foundation; director of the New York Genome Center; and Trustee Emeritus of Princeton University. He received an A.B. in chemistry from Princeton University and a Ph.D. in chemistry from the Massachusetts Institute of Technology.
Seth Feuerstein, , M.D., J.D.
arrow

Seth Feuerstein, , M.D., J.D.

Chief Medical Officer and Chief Innovation Officer, Magellan Healthcare and Yale University School of Medicine Department of Psychiatry
close
-
Dr. Feuerstein is a psychiatrist, entrepreneur and technology executive responsible for driving technology innovation within Magellan’s computerized cognitive behavioral therapy platform and programs. This portfolio is the leading behavioral change and engagement software suite used by millions of individuals throughout the U.S., U.K. and other health systems. Awarded the TripleTree iAward for Connected Health in the area of “Clinical Effectiveness,” this software was developed by Feuerstein’s team at Cobalt Therapeutics, a company he started and where he served as CEO until the company was acquired by Magellan in 2014. He also uses information technology in community service areas and founded a non-profit called Little Wonder, which improves the daily experience of cancer patients in treatment and helps patients and their loved ones create meaningful, powerful experiences together. His program has won several awards and has rapidly expanded to now serve 20 cancer centers. He holds medical and law degrees from New York University and completed his clinical training in psychiatry at the Yale University School of Medicine in New Haven, Conn., where he is a member of the clinical faculty.
Jeffrey A. Flaks
arrow

Jeffrey A. Flaks

Jeffrey A. Flaks, Executive Vice President and Chief Operating Officer, Hartford HealthCare
close
-
Mr. Flaks is the executive vice president and COO of Hartford HealthCare (HHC) where he is responsible for the system’s $2.5 billion operating budget and oversees all HHC operations, including five acute hospitals, a large physician practice, and multiple other healthcare services across three regions within Connecticut. He has been with Hartford HealthCare for 10 years, serving in previous roles as the president and CEO of Hartford Hospital, HHC’s flagship tertiary care center; the executive vice president and COO of Hartford Hospital and the executive vice president and COO of MidState Medical Center. In these roles Mr. Flaks achieved significant improvements in financial and operating performance and in quality and safety. He is also credited with championing HHC’s operating model “How Hartford HealthCare Works” (H3W) and driving the system’s cultural transformation. Previously, he held executive positions at Saint Vincent Catholic Medical Centers of New York and also held health care management positions at Beth Isreal in New York and the Detroit Medical Center in Michigan. Mr. Flaks is active in numerous community and professional organizations, is widely published and has been an invited speaker at numerous national and international conferences. He is a graduate of George Washington University with a master’s degree in health services administration and he received his Bachelor of Science degree at Ithaca College.
Marcia Fournier, Ph.D.
arrow

Marcia Fournier, Ph.D.

CEO and Founder, BIOARRAY Therapeutics Inc
close
-
Personalized medicine is what inspired Dr. Fournier to start a biotech company, BIOARRAY Therapeutics Inc. in Connecticut. She has over 15 years of experience in oncology and brings practical and strategic experience in drug discovery, biomarker development and clinical diagnostics. Prior to BIOARRAY, Dr. Fournier held a principal scientist position at GlaxoSmithKline, Oncology Center of Excellence for Drug Discovery. Her work as a postdoctoral fellow at UC Berkeley and doctoral fellow at the Dana-Farber Cancer Institute led to seminal peer-reviewed publications on oncology biomarker discovery. She is trained in genetics with a bachelor’s from Federal University of Rio de Janeiro.
Mark Friedlander, M.D., M.B.A.
arrow

Mark Friedlander, M.D., M.B.A.

Chief Medical Officer, Aetna Behavioral Health
close
-
Dr. Friedlander joined Aetna in 2002 as medical director for Aetna Behavioral Health. He is currently responsible for external relationships, strategic direction, oversight of patient management processes, quality management and accreditation, evaluation of new behavioral health technologies, and design and implementation of case and disease management programs. Dr. Friedlander is board certified in both Adult and Child/Adolescent Psychiatry. He is a recognized clinical leader in the field of Intellectual Disability and Neuropsychiatry and has been recognized as a "Top Doc" by Philadelphia Magazine.
Matthew Gevaert, Ph.D.
arrow

Matthew Gevaert, Ph.D.

CEO and Co-Founder, KIYATEC
close
-
Dr. Gevaert is CEO and co-founder of KIYATEC Inc., a life sciences company in Greenville, S.C. Previously, he led the commercialization of Clemson University’s biomedical and biotechnology intellectual property portfolio. He has experience with Merck, 3M and Dow Chemical, and been published in Science and the journal of the U.S. National Academy of Engineering. He graduated from the University of Waterloo with a bachelor’s degree in Applied Chemistry. He also holds a master’s degree and doctorate in Bioengineering from Clemson. He is an adjunct professor in Clemson’s Department of Bioengineering and a lecturer in its M.B.A. in Entrepreneurship & Innovation.
Paul Grundy, MD, MPH, FACOEM, FACPM
arrow

Paul Grundy, MD, MPH, FACOEM, FACPM

Founding President of Patient Centered Primary Care Collaborative and Director of IBM Global Healthcare Transformation
close
-
Dr. Paul Grundy is is the Global Director of HealthcareTransformation IBM Corporation where he develops and executes strategies thatsupport IBM’s transformation initiatives in the healthcare industry. Dr. Grundy is aHealthcare Ambassador for the Nation of Denmark and adjunct professor at theUniversity of Utah Department of Family and Preventive Medicine. He is amember of national Academy of Science’s Institute of Medicine, director of theACGME the body responsible for accrediting graduate medical trainingprograms, and member national advisory board of the National Center forInterprofessional Practice & Education. , Mayo Clinic Center for ConnectedCare (C3). Dr. Grundy is the President of the Patient-Centered Primary CareCollaborative (PCPCC). The PCPCC is a broad based coalition building PatientCenter Medical Home level care. He is a retired senior diplomat with the rank ofMinister Consular U.S. State Department.
Jill Hagenkord, MD, FCAP
arrow

Jill Hagenkord, MD, FCAP

Chief Medical Officer, 23 and Me
close
-
Dr. Jill Hagenkord is responsible for all medical affairs activities serving as the company liaison to physician, medical, genetics and research industry groups. Jill also oversees laboratory, shipping and fulfillment operations for 23andMe. Previously, Jill served as SVP of medical strategy for InVitae Corporation, a genetics information company, where her role included serving as medical director, contributing to corporate strategy, acting as commercial liaison, and leading the company's physician education programs. Jill is a board-certified molecular genetic pathologist. Prior to joining Invitae, she served as CMO and senior vice president at Complete Genomics, Inc. Her other prior experiences include founder and CMO for iKaryos Diagnostics, associate professor of pathology at Creighton University School of Medicine, director of molecular pathology and clinical genomics at Creighton Medical Laboratories, and pathologist at Deltagen, Inc. Jill received her M.D. from Stanford University School of Medicine in 1999, did her residency training in pathology at the University of California at San Francisco and the University of Iowa, and completed fellowships in pathology/oncology informatics and molecular genetic pathology at the University of Pittsburgh Medical Center.
Benjamin Heywood
arrow

Benjamin Heywood

Co-Founder and President, Patients Like Me
close
-
During its 10 year history, Ben has overseen all stages of PatientsLikeMe’s growth, including financing, the expansion of patient communities, and business partnerships. Today he defines the company's product strategy and roadmap and directs the user experience (UX) and engineering teams. Combined, these roles ensure PatientsLikeMe's website continuously evolves to meet patient needs, and that the patient voice continues to define value in healthcare. Ben also serves as the company’s Chief Privacy Officer. Ben is a frequent speaker at conferences and an expert source for media on patient issues and patient-centered care. Earlier in his career, he served in manufacturing and business development roles at Target Therapeutics, the leading designer and manufacturer of microcatheter-based products for the treatment of stroke, which was later acquired by Boston Scientific. He earned his bachelor’s degree in Mechanical Engineering from the Massachusetts Institute of Technology (MIT) and his master’s degree in Business Administration from UCLA’s Anderson Graduate School of Management
Christopher Hocevar
arrow

Christopher Hocevar

President, Cigna Pharmacy Management; President, Select Segment, Cigna Corporation
close
-
Mr. Hocevar is the president of Cigna Pharmacy Management, the company’s pharmacy benefits management business and president of Cigna's Select Segment, which focuses on benefit solutions for groups with 25-250 employees. He has led the U.S. Individual and Family Plan Segment and the Emerging Markets Segment, and served as the business merger and acquisition lead for several of Cigna's acquisitions/partnerships. Previously, he analyzed international insurance markets and risks for Deloitte Consulting. Mr. Hocevar earned his Bachelor of Business Administration in Accounting from the University of Toledo and earned his Master of Business Administration from the Weatherhead School of Management.
Jill Rubin Hummel
arrow

Jill Rubin Hummel

President and General Manager, Anthem Blue Cross and Blue Shield in Connecticut
close
-
Ms. Hummel is president of Anthem Blue Cross and Blue Shield where she is responsible for operations, including sales, underwriting, managing external relationships with key stakeholders and guiding efforts to transform healthcare. Previously, she was vice president of Payment Innovation for Anthem, Inc., where she was accountable for developing provider payment and delivery models that reward and support improvements in health care quality, patient safety and health outcomes, while reducing healthcare costs. She serves on the board and is vice chair-elect for the Patient-Centered Primary Care Collaborative, and she serves on the board of directors for the Governor’s Prevention Partnerships.
Praduman Jain
arrow

Praduman Jain

CEO, Vibrent Health
close
-
Mr. Jain is the CEO of Vibrent, which provides “consumer-centered” precision health and precision medicine solutions for personal and population health. This advanced bioinformatics learning health system delivers evidence-based, clinical and behavior change programs outside the clinic walls, using mobile phones. Mr. Jain was the founding chair of mHealth initiative of Continua Health Alliance, an open industry alliance of 240 healthcare and technology organizations driving interoperability guidelines. He has held a variety of senior leadership roles at Clearwire, Sprint, Nextel, AOL, Time Warner and VTech. Mr. Jain holds several patents and M.S., B.S. degrees in Electrical Engineering.
Steven Kafka, Ph.D.
arrow

Steven Kafka, Ph.D.

Chief Operating Officer, Foundation Medicine
close
-
Chief Operating Officer, Foundation Medicine. Dr. Kafka has over 15 years of business and strategy experience in the pharmaceutical and biotechnology industries, with a focus on \oncology. He was previously chief operating officer and chief financial officer at Aileron Therapeutics, where he led the operations, finance, and human resources functions.
Martin Kohn, M.D.
arrow

Martin Kohn, M.D.

Chief Medical Scientist, Sentrian
close
-
Dr. Martin Kohn is Chief Medical Scientist at Sentrian, winner of the 2015 Innovation in remote patient care award from the American Telemedicine Association. His research includes predictive analytics and expert systems in the clinical decision process. Dr. Kohn is a board-certified emergency physician withover 30 years of practice and management experience. He is certified in Clinical Informatics and has published multiple articles and book chapters on clinical, technical and management subjects. He was recently named one of the 16 healthcare data-driven "geeks" to watch by Healthcare IT News.
Ranga Krishnan, M.B., C.h.B.
arrow

Ranga Krishnan, M.B., C.h.B.

Professor, Neuroscience and Behavioral Disorders Program, Duke – NUS Singapore
close
-
Dr Krishnan is currently Professor of Psychiatry and Behavioral Sciences Duke University and Duke-NUS, Singapore and previously Dean of Duke-NUS Graduate Medical School, Singapore. He is Chairman National Medical Research Council Singapore. Dr Krishnan was previously Chair of Psychiatry and Behavioral Sciences at Duke from 1998 to 2009. Dr Krishnan is a member of the Institute of Medicine, National Academy of Sciences. He has received numerous awards and honors for his work including the Laughlin Fellow, American College of Psychiatry, Rafaelsen Award Collegium Internationale Neuro-Psychopharmacologicum (CINP,) Brain Behavior Research Foundation National Alliance for Research on Schizophrenia and Depression (NARSAD) Distinguished Investigator Award Depression and Bipolar Support Alliance DBSA Klerman Award, American Association for Geriatric Psychiatry. (AAGP) Distinguished Scientist Award, Charles Burlingame Award and the American College of Psychiatry Research Award in Geriatric Psychiatry. American College of Psychiatry Research Award in Mood Disorders. Dr Krishnan has conducted research primarily in the area of late life depression, Bipolar disorder and dementia. He is an authority on the use of imaging in the diagnosis and treatment of mood disorders. He is well recognized for his work establishing the interplay between vascular disease and depression. He has published over 450 articles and numerous chapters. He has also been instrumental in creating new ways to diagnose and treat mental health disorders.
Bruce T. Liang, M.D., F.A.C.C.
arrow

Bruce T. Liang, M.D., F.A.C.C.

Dean, UConn School of Medicine
close
-
Dr. Bruce T. Liang, an internationally recognized cardiologist and researcher, is the Dean of the UConn School of Medicine. He is the Director of the Pat and Jim Calhoun Cardiology Center, Chief of the Division of Cardiology and serves as the Ray Neag Distinguished Professor of Vascular Biology and Cardiology at UConn Health.Dr. Liang served as Interim Dean in 2011 and 2015 and was appointed as Dean in June 2015 by Provost Mun Choi. He is a fellow of the American College of Cardiology, the American Heart Association and the Council on Clinical Cardiology and Basic Cardiovascular Sciences. Dr. Liang is also an elected member of the American Society for Clinical Investigation, of the Association of University Cardiologists, and of the Connecticut Academy of Science and Engineering.After 13 years with the University of Pennsylvania School of Medicine where he served as an associate professor both of medicine and pharmacology and was actively involved with research, patient care and teaching, he joined the UConn Health Center in 2002.He is widely published in the areas of cell biology and pharmacology of the cardiovascular system, as well as translational research in heart failure. In research, he has been continuously funded since 1986 by the National Institutes of Health, the American Heart Association and the Department of Defense. Dr. Liang was the lead investigator of a clinical research study conducted at the UConn Health Center that identified a protein fragment that when detected in the blood can be a predictor of heart attack. The study was published in the Journal of the American College of Cardiology.Dr. Liang has been consistently named an America’s Top Doctor by Castle Connolly in cardiovascular disease since 2003, and has been recognized as a Best Doctor in America by Best Doctor, Inc. Dr. Liang received his medical degree from Harvard Medical School. He completed his residency at the Hospital of the University of Pennsylvania, and cardiology fellowship at Brigham and Women’s Hospital and Harvard Medical School.
Andrew Lo, Ph.D.
arrow

Andrew Lo, Ph.D.

Professor of Finance, and Director, Laboratory for Financial Engineering, MIT Sloan School of Management
close
-
Dr. Lo's research interests include the empirical validation and implementation of financial asset pricing models; hedge-fund risk and return dynamics and risk transparency; and, most recently, evolutionary and neurobiological models of individual risk preferences and financial markets.
Christopher Loose, Ph.D.
arrow

Christopher Loose, Ph.D.

Assistant Professor of Urology, Lecturer in Biomedical Engineering and Executive Director of CBIT, Yale University
close
-
Dr. Loose serves as executive director of the Yale Center for Biomedical and Interventional Technology. He is also an Accelerator executive at the Center for Integration of Medicine and Innovative Technology (CIMIT). While earning his Ph.D. in Chemical Engineering at MIT, Dr. Loose co-founded Semprus Biosciences and served as CTO through its acquisition and FDA approval of an anti-clotting vascular catheter. Prior to his graduate work, Dr. Loose was a chemical engineer at Merck Research Labs after graduating summa cum laude with a B.S.E. in Chemical Engineering from Princeton University.
John MacPhee, MPH, MBA
arrow

John MacPhee, MPH, MBA

CEO, JED Foundation
close
-
John MacPhee serves as CEO of The JED Foundation, a non-profit that exists to promote emotional health and prevent suicide among teens and young adults. Prior JED, he served as president of Strativa Pharmaceuticals, where he oversaw commercial operations, clinical development, medical affairs and business development. Previously, he worked at Forest Laboratories, where he led the launches of treatments for depression, anxiety and Alzheimer's disease. John also serves as a board member of Adamas Pharmaceuticals, BlackThorn Therapeutics, and as an advisor to several charities. He earned a BA and MPH from Columbia University, and an MBA from New York University.
Brendan Maher
arrow

Brendan Maher

Associate Professor of Law and Robert D. Paul Scholar, UConn School of Law
close
-
Professor Maher is a professor of Law and the director of UConn's independently endowed Insurance Law Center. A graduate of Stanford University and Harvard Law School, Professor Maher is a nationally recognized expert in the regulation of insurance, pensions and healthcare. He is a leading authority on the meaning of both ERISA and the Affordable Care Act. He routinely appears before the United States Supreme Court to litigate cases involving ERISA, the federal statute governing employee benefits.
Lawrence J. Markson, MD, MPH
arrow

Lawrence J. Markson, MD, MPH

CMIO and Vice President, Clinical Information Systems
close
-
Dr. Markson is the chief medical information officer and vice president for Clinical Information Systems at Beth Israel Deaconess Medical Center (BIDMC). Dr. Markson oversees all of the hospital’s clinical systems, including its web-based electronic health record, its personal health record, its healthcare information exchange, and its data warehousing and analytics operations. BIDMC has a long history of clinical IT innovation, was the first hospital in the country to achieve meaningful use, and was one of the first hospitals to invite patients to view provider visit notes through its patient portal.
David McCallie Jr., M.D.
arrow

David McCallie Jr., M.D.

Senior Vice President, Medical Informatics, Cerner Corporation
close
-
Dr. David McCallie, senior vice president, Medical Informatics, is director of the Cerner Medical Informatics Institute. He is responsible for a research and development team focused on developing innovations at the intersection of computer science and clinical medicine. His most recently completed project was the design of Cerner’s ePrescribing system and the Community Health Record. He is currently working on the definition of the next generation of personal health records, known as Independent Health Record Trusts.Dr. McCallie joined Cerner in 1991. He was previously responsible for the development of Cerner’s clinical nomenclature system and the PowerNote™ structured clinical documentation tool. He also was the chief architect for open clinical foundation, Cerner’s clinical data repository. He is a member of Cerner’s architecture cabinet.Prior to joining Cerner, McCallie was director of research computing at Children’s Hospital in Boston, Mass., and an instructor in neurology at Children’s Hospital and Harvard Medical School. His research background includes using computers to create three-dimensional models of seizure-induced brain electrical activity.McCallie earned a bachelor’s degree in electrical engineering and computer science at Duke University. He earned his medical degree at Harvard Medical School. McCallie has published numerous articles and presented frequently on the subject of healthcare informatics. He is a member of the American Medical Informatics Association.
Gregory Moore, M.D., Ph.D.
arrow

Gregory Moore, M.D., Ph.D.

Chief Emerging Technology Officer, Geisinger Health System
close
-
Dr. Moore serves as chief emerging technology and informatics officer for Geisinger Health System and director of Geisinger’s Institute for Advanced Application. Dr. Moore continues to practice as a diagnostic neuroradiologist and maintains an active research program as an Abigail Geisinger clinician investigator. Dr. Moore served as vice chair of Radiology for Geisinger Health System. He held appointments at Los Alamos National Laboratory, Wayne State University School of Medicine and at Penn State University where he was a tenured professor in the College of Medicine. Dr. Moore received his Ph.D. from the Massachusetts Institute of Technology (MIT) and his M.D. at Wayne State University School of Medicine followed by residency training at Penn State University College of Medicine.
Kush Parmar, MD, PhD
arrow

Kush Parmar, MD, PhD

Partner, 5AM Ventures
close
-
Dr. Parmar is a Partner at 5AM Ventures. He joined 5AM from Harvard Medical School, where he was an NIH-sponsored M.D./PhD Physician Scientist Fellow in the joint Harvard-MIT Health Sciences and Technology Program. Dr. Parmar currently serves as a Director or Observer on the Boards of Arvinas, Audentes, Novira, Pulmatrix and scPharmaceuticals. He previously served as Board Observer for Achaogen (NASDAQ: AKAO) and Envoy (acquired by Takeda). He is a Fellow of the Society of Kauffman Fellows. Dr. Parmar is a member of the Scientific Advisory Council of Princeton University's Department of Molecular Biology and the Grace Wilsey Foundation. He also founded a non-profit international development organization, the Cruz Blanca Initiative. He holds an A.B. in Molecular Biology and Medieval Studies from Princeton University, a PhD in Experimental Pathology from Harvard University, and an M.D. from Harvard Medical School. Dr. Parmar is based in Boston.
Steven Quake, Ph.D.
arrow

Steven Quake, Ph.D.

Stanford University Professor of Bioengineering and Applied Physics, and Investigator, Howard Hughes Medical Institute
close
-
Dr. Quake has founded or co-founded several companies, including Fluidigm, Helicos Biosciences, Verinata Health, Quanticel Pharmaceuticals, Moleculo, Cellular Research and Immumetrix.
Jack Reed
arrow

Jack Reed

President and CEO, ProHealth Physicians
close
-
Jack Reed is the President and Chief Executive Officer of ProHealth Physicians, Inc., one of the largest primary care systems in the Northeast. He has extensive experience in the development, implementation and management of health related businesses including those in managed care and provider/hospital networks. Prior to his role at ProHealth Physicians, Mr. Reed was a founder and President/CEO of HealthDIRECT, Inc., a managed care company that provides systems and services for workers compensation and disability carriers. He was the former President/CEO of the VHA of Southern New England, a regional health care network organized by twelve Connecticut hospitals. The VHA of Southern New England was responsible for the development of health-related companies and programs for managed care services, home infusion therapy, disability management and other hospital management and ancillary services. In this capacity, Mr. Reed facilitated and chaired the development of a statewide HMO, which was later acquired by Aetna Health Plans. Mr. Reed was formerly an executive for the Detroit Medical Center. At the DMC, he held several positions in administration and within their for-profit subsidiary, Radius Health Care. While working with Radius, he had a key role in the acquisition, operation and/or integration of a series of health care services including multi and single specialty group practices, physician offices, nursing homes, home health care and management service programs. Mr. Reed holds an MBA from Rensselaer Polytechnic Institute, Troy, New York and a BS in Economics from Siena College, Loudonville, New York.
Mostafa Ronaghi, Ph.D.
arrow

Mostafa Ronaghi, Ph.D.

Chief Technology Officer and Senior Vice President, Illumina
close
-
Dr. Ronaghi is senior vice president and chief technology officer at Illumina; he is responsible for leading internal research and the Illumina accelerator program. He co-founded Avantome, a privately held sequencing company and NextBio, a search engine for life science data, among others. He was a principal investigator at Stanford University. He serves on the board of directors of Aurora Algae and BaseHealth. He earned his Ph.D. from the Royal Institute of Technology in Sweden. He holds more than 30 (pending and issued) patents and has written more than 70 peer-reviewed publications in journals and books.
Juan C. Salazar, M.D., M.P.H., F.A.A.P.
arrow

Juan C. Salazar, M.D., M.P.H., F.A.A.P.

Physician-in-Chief, Connecticut Children's Medical Center
close
-
Dr. Salazar is the chair of the Department of Pediatrics at the University of Connecticut School of Medicine and physician-in-chief at Connecticut Children’s Medical Center. In addition to these roles, Dr. Salazar is a professor of Pediatrics and Immunology and division head of Pediatric Infectious Diseases, and director of the Pediatric and Youth HIV Program at Connecticut Children’s.
Richard Salmon, M.D., Ph.D.
arrow

Richard Salmon, M.D., Ph.D.

Vice President and National Medical Executive for Performance Measurement and Improvement. Cigna
close
-
Dr. Salmon is vice president and national medical executive for Performance Measurement and Improvement at Cigna. He has held several other positions at Cigna. Previously, he was senior vice president and chief medical officer for the HMO HealthSource. He was assistant professor of family medicine and chief resident in family practice at Case Western Reserve University and its affiliated University Hospital. He is board-certified in family practice and earned his medical degree and Ph.D. in biomedical engineering from Case Western Reserve University. He holds a Bachelor of Science degree in engineering and a Bachelor of Arts degree from Princeton University.
David Shaywitz, M.D., Ph.D.
arrow

David Shaywitz, M.D., Ph.D.

Chief Medical Officer, DNAnexus
close
-
Dr. Shaywitz is chief medical officer at DNAnexus, and holds an adjunct appointment as Visiting Scientist in the Department of Biomedical Informatics at Harvard Medical School. He has a decade of experience in the life science industry, with experience in R&D, strategy, and commercial operations through his work at Merck, the Boston Consulting Group, and Theravance. Dr. Shaywitz received his MD/PhD from Harvard and MIT, and trained in internal medicine and endocrinology at the Massachusetts General Hospital. He is co-author, with Lisa Suennen, of "Tech Tonics: Can Passionate Entrepreneurs Heal Healthcare With Technology?", and co-host, with Lisa Suennen, of "Tech Tonics," a twice-a-month podcast focused on the people and passion at the intersection of technology and health, and available on iTunes.
Catherine Smith
arrow

Catherine Smith

Commissioner, Department of Economic and Community Development
close
-
Catherine Smith is the Commissioner of the Connecticut Department of Economic and Community Development (DECD), the lead state agency responsible for attracting and retaining businesses and jobs, revitalizing neighborhoods and communities, and fostering appropriate development in Connecticut’s towns and cities. Governor Dannel P. Malloy appointed her to the position in April 2011. Commissioner Smith’s top economic development priorities are to strengthen the state’s efforts to nurture and drive innovation; effectively promote and market the state’s many business advantages within Connecticut and beyond its borders; and place a renewed emphasis on all aspects of customer service in order to make the state more business-friendly and attractive for investment. Her community development priorities include improving the state’s ability to redevelop brownfields, continuing the state’s commitment to responsible growth and transit-oriented development and fostering arts and culture to make our cities more vibrant and attractive. The commissioner is forging closer working relationships with private sector partners to realize these objectives and to maximize the return on state investments. Prior to joining DECD, Commissioner Smith had a distinguished career in the insurance and financial services industry. She began her career at Aetna in 1983 and held various management positions, including investment officer and chief financial officer for Aetna Financial Services. Later at ING she served in numerous leadership positions including chief operating officer for ING U.S. Financial Services, and CEO of the U.S. Insurance businesses. In 2008 Smith was named CEO of ING U.S. Retirement Services, one of the largest defined contribution plan managers in the United States with more than $280 billion in assets under management and administration. Smith graduated from Hampshire College in Amherst, Massachusetts, and received a Master’s degree in public and private management from the Yale School of Management in New Haven, Connecticut. Smith has been a frequent speaker at industry conferences and in the media and has been recognized by U.S. Banker magazine’s “Top 25 Most Powerful Nonbank Women in Finance”. Smith is a board member of Outward Bound, USA.
Michael Sturmer
arrow

Michael Sturmer

Vice President, Consumer Engagement, Cigna
close
-
As vice president for Consumer Health Engagement, Mr. Sturmer is responsible for development and implementation of a Consumer Health Engagement Strategy focused on redefining how consumers engage with their health, Cigna and the broader health ecosystem. Over the course of his career, he has held various leadership roles within IT. He represents Cigna in the Northeast Business Group on Health payer and provider collaborative and is part of the IHI Collaborative focused on innovation to drive better health and lower cost for patients with complex needs. He holds an associate’s degree in Nursing and a bachelor’s degree in Health Administration.
Allen Tien, MD, MHS
arrow

Allen Tien, MD, MHS

Founder, President, and Director of Applied Research of Medical Decision Logic, Inc. (“mdlogix”)
close
-
Dr. Tien is Founder, President, and Director of Applied Research of Medical Decision Logic, Inc. (“mdlogix”). As well as being a Board-Certified psychiatrist, he has Master's level training in biostatistics and postdoctoral training in psychiatric epidemiology, research design and methods, and public mental health issues. Dr. Tien was a full-time tenure-track faculty member in the Johns Hopkins University School of Public Health Department of Mental Hygiene and School of Medicine Department of Psychiatry from 1988 to 1997, promoted to Associate Professor in 1996. Active in research in public mental health epidemiology, services, and prevention, and clinical neuroscience, for a number of years he taught a key Mental Hygiene course on multi-level etiologic models of mental disorders. He has been developing both software and hardware for computer-based assessment systems since 1987, and is knowledgeable about information technology design and engineering. He conceived of and continues to lead a number of Small Business Innovation Research (SBIR) projects that address psychometrics and the assessment of symptoms, diagnostic and treatment logic, indexed audio and video recording and playback, data management, graph (e.g., social networks, genetic networks) visualization, software tools for social network analysis (SNA), multi-level integration of genetic and phenotype data, nursing workflow, patient education, primary care behavioral health screening, and patient reported outcomes for palliative and hospice care. He provided the vision and leadership at mdlogix for the development of the Health Science Process Framework (HSPF). A major result is the mdlogix Clinical Research Management System (CRMS), a proven enterprise-scale integrated web solution for unlimited multi-site study protocols, multi-role team workflows, study level data collection, reporting, management, and analysis, integrated financial management, and compliance and institutional monitoring and reporting. Furthermore, Dr. Tien has led the vision for and use of CRMS-HSPF as the translational platform for clinical care and public health projects and programs, the flourishing example being www.BH-Works.com, a solution for validated comprehensive assessment of patients for depression, alcohol, and other behavioral health risks and mental illness problems, currently being used and expanded across eight states. Dr. Tien also led the creation of the www.SocioWorks.com system for the efficient application of social network science methods.
Brad Tritle
arrow

Brad Tritle

President and CEO, Vitaphone
close
-
Mr. Tritle serves as president/CEO for vitaphone e-health solutions, an international, mobile telehealth and patient engagement firm. He is co-author of the HIMSS book Engage! Transforming Healthcare through Digital Patient Engagement, and has chaired both the HIMSS Patient Generated Health Data and Healthcare Social Media task forces. Prior to vitaphone, he served as a health IT consultant to HHS, for-profit companies and non-profit organizations. His past positions include serving as CEO of eHealthTrust, executive director of Arizona Health-e Connection, and in other corporate and government leadership. Mr. Tritle is a Certified Information Privacy Professional (CIPP/US).
Rick Weisblatt, Ph.D.
arrow

Rick Weisblatt, Ph.D.

Chief of Innovation and Strategy, Harvard Pilgrim Health Care
close
-
Dr. Rick Weisblatt is Chief of Innovation and Strategy for Harvard Pilgrim Health Care, New England’s leading not-for profit health plan. Dr. Weisblatt is responsible for actively identifying and assessing new innovation opportunities based on emerging trends. He leads the development and monitoring of Harvard Pilgrim’s long term strategic plan. Dr. Weisblatt also directs the Harvard Pilgrim provider strategy and recently implemented new risk arrangements intended to align the interests of physicians, health plans and patients. Dr. Weisblatt led the development of new network products including limited and tiered designs, health engagement incentive programs, transparency tools and member steerage programs. More recently, he has led efforts to deepen Harvard Pilgrim’s provider relationships including a joint venture with major health care systems in New Hampshire which features new models for collaborative population health management.Dr. Weisblatt is a frequent speaker and trusted adviser to policy makers, regulators and elected officials on such subjects as health care reform, behavioral health, market competition and health care cost trends.Dr. Weisblatt has a doctorate in clinical psychology from the University of Maryland and his clinical interests have been in treating children, adolescents and couples. Founded in 1969, Harvard Pilgrim and its affiliates are licensed to provide comprehensive health insurance solutions in Massachusetts, Maine, New Hampshire and Connecticut. Its provider network has more than 32,000 physicians and 150 hospitals. Harvard Pilgrim and its affiliates offer health and benefit plan solutions to over 1 million members in New England. It was awarded NCQA’s Number One Health Plan in the nation ten years in a row.

arrow

Description
close
info:
Featured Speaker: Thomas Daschle
arrow

Featured Speaker: Thomas Daschle

Former Senator, South Dakota and Founder and CEO of The Daschle Group
close
info:
Senator Daschle is the Founder and CEO of The Daschle Group, A Public Policy Advisory of Baker Donelson. Senator Daschle served his home state, South Dakota, in the U.S. House of Representatives from 1979 until 1987 and in the U.S. Senate from 1987 to 2005. He is one of only two Senators to have served twice as both Majority and Minority Leader. In addition, Senator Daschle is Chair of the Board of Directors at the Center for American Progress, Vice-Chair for the National Democratic Institute and a co-founder of the Bipartisan Policy Center. He is the author of Like No Other Time: The 107th Congress and the Two Years That Changed America Forever; Critical: What We Can Do About the Health-Care Crisis; Getting It Done: How Obama and Congress Finally Broke the Stalemate to Make Way for Health Care Reform and U.S. Senate: Fundamentals of American Government. He has co-authored his most recent book, Crisis Point, with former Senator Trent Lott.
Featured Speaker: Glenn Steele, Jr. M.D., Ph.D.
arrow

Featured Speaker: Glenn Steele, Jr. M.D., Ph.D.

Chairman of the Board and Chief, Corporate Strategy, xG Health Solutions, Inc
close
info:
Glenn D. Steele, Jr., MD, PhD, is the Chairman of xG Health Solutions. From 2001-2014, he served as President and Chief Executive Officer of Geisinger Health System, an integrated health services organization nationally recognized for the development and implementation of innovative care models.​Glenn previously served as Dean of the Biological Sciences Division and the Pritzker School of Medicine and Vice President for Medical Affairs at the University of Chicago, as well as the Richard T. Crane Professor in the Department of Surgery. Prior to that, he was the William V. McDermott Professor of Surgery at Harvard Medical School, President and Chief Executive Officer of Deaconess Professional Practice Group, Boston, MA., and Chairman of the Department of Surgery at New England Deaconess Hospital, Boston, MA. Glenn is past Chairman of the American Board of Surgery. His investigations have focused on the cell biology of gastrointestinal cancer and pre-cancer, and most recently on innovations in healthcare delivery and financing. A prolific writer, he is the author or co-author of more than 488 scientific and professional articles.​A member of the National Academy of Medicine, Glenn serves as a member of the Roundtable on Value and Science-driven Healthcare, the Committee on the Governance and Financing of Graduate Medical Education, the Vital Directions for Health and Health Care Steering Committee, and previously served on the Committee on Reviewing Evidence to Identify Highly Effective Clinical Services (HECS). A fellow of the American College of Surgeons, he is a member of the American Surgical Association, the American Society of Clinical Oncology, and Past President of the Society of Surgical Oncology.Glenn serves on the following boards and national committees: Director, Agency for Integrated Care (AIC) Singapore, Cepheid; Director, City of Hope; Member, Emory University’s Healthcare Innovation Program (HIP) External Advisory Board; Director, Healthcare Executives Network; Director, IngeniousMed; Member, Institute for Healthcare Optimization Advisory Board; Honorary Chair, Pennsylvania March of Dimes Prematurity Campaign; Director, PTC Therapeutics; Director, Stratus Video Interpreting; Member, the Peterson Center on Healthcare Advisory Board; Director, the State Health Care Cost Containment Commission, Wellcare Health Plans Inc.; and Member, Steering Committee of Vital Directions for Health and Health Care.​Glenn received his bachelor’s degree in history and literature from Harvard College and his medical degree from New York University School of Medicine. He completed his internship and residency in surgery at the University of Colorado, where he was also a fellow of the American Cancer Society. He earned his doctorate in microbiology at Lund University in Sweden.
arrow

Description
close
info:
Content
Edward Abrahams, Ph.D.
arrow

Edward Abrahams, Ph.D.

President, Personalized Medicine Coalition
close
info:
Edward Abrahams, Ph.D., is the president of the Personalized Medicine Coalition (PMC). Representing innovators, scientists, patients, providers and payers, PMC promotes the understanding and adoption of personalized medicine concepts, services and products to benefit patients and the health system. It has grown from its original 18 founding members in 2004 to more than 225 today.Previously, Dr. Abrahams was the executive director of the Pennsylvania Biotechnology Association, where he spearheaded the successful effort that led to the Commonwealth of Pennsylvania’s investment of $200 million to commercialize biotechnology in the state. Earlier, he had been assistant vice president for federal relations at the University of Pennsylvania and held a senior administrative position at Brown University.Dr. Abrahams worked for seven years for the U.S. Congress, including as a legislative assistant to Senator Lloyd Bentsen, an economist for the Joint Economic Committee under the chairmanship of Representative Lee Hamilton, and as a AAAS Congressional Fellow for Representative Edward J. Markey.The author of numerous essays, Dr. Abrahams serves on the editorial board of Personalized Medicine and has taught history and public policy at Brown University and the University of Pennsylvania.
Mark Adams, Ph.D.
arrow

Mark Adams, Ph.D.

Professor and Campus Director, J. Craig Venter Institute
close
info:
Dr. Mark Adams is Professor and Campus Director for the J. Craig Venter Institute in La Jolla, California. Dr. Adams comes from a rich background including industry, government, academic, and nonprofit settings. Dr. Adams was one of the founding scientists of The Institute for Genomic Research and of Celera Genomics, where he directed the large-scale sequencing and genome annotation groups. At JCVI he leads the bacterial genomics programs with a particular emphasis on evolutionary approaches to understanding the spread of multidrug-resistant bacteria.
David Beier, JD
arrow

David Beier, JD

Managing Director, Bay City Capital
close
info:
David Beier, JD is a Managing Director of Bay City Capital and has been with the firm since 2013. He is a globally recognized leader in health care policy, pricing, intellectual property, government affairs, regulatory affairs, health care economics, and product commercialization. In addition, having spent two decades as part of the senior management teams for Amgen and Genentech, the two largest biotechnology companies in the world, he contributes invaluable perspective regarding strategy for entrepreneurial biotechs, the needs of potential acquirers, and the global health care industry in general.Mr. Beier served in the White House as the Chief Domestic Policy Advisor to Vice President Al Gore during the Clinton Administration. He has served as an appointee of President Clinton on his Advisory Committee for Trade Policy and Negotiations, on the Institute of Medicine panel on the Future of Health and Human Services, and as an advisor to the President’s Council of Advisors on Science and Technology. Mr. Beier was also formerly a partner in international law firm Hogan and Hartson and was formerly Counsel to the US House of Representatives Committee on the Judiciary.He has testified before Congress and the Federal Trade Commission, has written numerous law review articles and technical legal works, is regularly invited to author expert OpEds on health care, and has contributed to books on topics ranging from intellectual property, trade, privacy and justice issues.He currently serves as an appointee of Governor Brown on the California State Government Organization and the Economy Commission, as a Fellow of the Center for Global Enterprise, and teaches as an Adjunct Lecturer at the Haas School of Business at UC Berkeley.Mr. Beier received his JD from Albany Law School at Union University and his undergraduate degree and Colgate University. He is admitted to practice law in New York and the District of Columbia.
Morris Birnbaum, M.D., Ph.D.
arrow

Morris Birnbaum, M.D., Ph.D.

Senior Vice President and Chief Scientific Officer, Cardiovascular and Metabolic Disease Research Unit, Pfizer
close
info:
Morris J. Birnbaum, M.D., Ph.D. is Senior Vice President and Chief Scientific Officer of the Cardiovascular and Metabolic Disease (CVMED) Research Unit at Pfizer, which focuses on developing therapies to treat, slow or prevent disease progression and improve the quality of life of patients with obesity, type 2 diabetes (T2D), cardiovascular (CV) and kidney diseases. Dr. Birnbaum is a leading researcher in the signals that regulate and integrate metabolic pathways in liver, muscle and adipose tissue, and how they are disrupted in insulin resistant states.Dr. Birnbaum completed his undergraduate, graduate and medical training at Brown University in Providence, R.I. before moving to San Francisco for postdoctoral studies at the University of California. Following an associate professorship at Harvard Medical School, he went to the University of Pennsylvania as professor of Medicine. Dr. Birnbaum is currently the associate dean for Biomedical Cores and associate director of the Institute for Diabetes, Obesity and Metabolism. He was elected to membership in the Association of American Physicians in 2003 and made a fellow of the AAAS in 2007.
Stephen Bloch, M.D.
arrow

Stephen Bloch, M.D.

General Partner, Canaan Partners
close
info:
A former entrepreneur and practicing physician, Steve knows firsthand the challenges of building successful healthcare companies. Unfazed by the complexity in healthcare, whether regulatory, scientific or technical, Steve's mission at Canaan is to find companies that make healthcare delivery more efficient. Steve currently serves on the boards of companies in Digital Health (Truveris, DICOM Grid); BioPharma (Envisia, Liquidia, LQ3 and Marinus Pharmaceuticals (NASDAQ: MRNS)); Medical Devices (Mitraspan); and Diagnostics (Sample6). Before joining Canaan in 2002, Steve founded multiple start-ups, including Radiology Management Sciences (RMS), a pioneer in managing radiology benefits for health plans, where he was CEO for 6 years. Steve also helped start OmniSonics Medical Technologies, which engineered novel ultrasonic catheters for treating vascular occlusive disease, and he co-founded TeleRad, an early teleradiology services company. Prior to embarking on startups, Steve was a strategic consultant for the Arthur D. Little firm. Steve was a Ewing Marion Kauffman Fellow, an educational program to develop future leaders in venture capital.Steve obtained his AB from Dartmouth College, his MA in the history of science and public policy from Harvard, and his medical degree from the University of Rochester. Steve trained in medicine at Massachusetts General Hospital/Harvard Medical School (radiology) and Lenox Hill Hospital/Cornell Medical School (internal medicine).
Randy Burkholder
arrow

Randy Burkholder

Vice President, Policy and Research, PhRMA
close
info:
Randy Burkholder is Vice President of Policy and Research at the Pharmaceutical Research and Manufacturers of America. Mr. Burkholder leads PhRMA work on policy solutions for supporting continued biopharmaceutical innovation and high-quality, patient-centered health care, including payment and delivery reform, quality measurement, appropriate use and patient adherence, evidence-based medicine and health technology assessment, value of innovation and personalized medicine. Mr. Burkholder represents PhRMA at federal agencies and advisory bodies including the Medicare Evidence Development and Coverage Advisory Committee, CMS’ Technical Expert Panel on oncology, and the Federal Coordinating Council for Comparative Effectiveness Research. He also is a former member of the Board of Directors of the Personalized Medicine Coalition and serves on the Steering Committee of the Partnership to Improve Patient Care and the advisory committee for the Turning the Tide Against Cancer initiative. Mr. Burkholder has over 20 years' experience in health care policy, advocacy and communications in the medical technology and pharmaceutical industries.Prior to joining PhRMA, Mr. Burkholder was Associate Vice President for Public Affairs at AdvaMed, the leading association of the medical device and diagnostics industries.
Robert M. Califf, MD, MACC
arrow

Robert M. Califf, MD, MACC

Commissioner, U.S. Food and Drug Administration
close
info:
Robert M. Califf, MD, MACC, is the Food and Drug Administration's commissioner of food and drugs. As the top official of the FDA, Dr. Califf is committed to strengthening programs and policies that enable the agency to carry out its mission to protect and promote the public health.Previously, Dr. Califf served as the FDA’s Deputy Commissioner for Medical Products and Tobacco from February 2015 until his appointment as commissioner in February 2016. In that capacity, he provided executive leadership to the Center for Drug Evaluation and Research, the Center for Biologics Evaluation and Research, the Center for Devices and Radiological Health, and the Center for Tobacco Products. He also oversaw the Office of Special Medical Programs and provided direction for cross-cutting clinical, scientific, and regulatory initiatives, including precision medicine, combination products, orphan drugs, pediatric therapeutics, and the advisory committee system.Prior to joining the FDA, Dr. Califf was a professor of medicine and vice chancellor for clinical and translational research at Duke University. He also served as director of the Duke Translational Medicine Institute and founding director of the Duke Clinical Research Institute. A nationally and internationally recognized expert in cardiovascular medicine, health outcomes research, healthcare quality, and clinical research, Dr. Califf has led many landmark clinical trials and is one of the most frequently cited authors in biomedical science, with more than 1,200 publications in the peer-reviewed literature.Dr. Califf has served on the Institute of Medicine (IOM) committees that recommended Medicare coverage of clinical trials and the removal of ephedra from the market, as well as on the IOM Committee on Identifying and Preventing Medication Errors and the IOM Health Sciences Policy Board. He has served as a member of the FDA Cardiorenal Advisory Panel and FDA Science Board’s Subcommittee on Science and Technology. Dr. Califf has also served on the Board of Scientific Counselors for the National Institutes of Health and the National Library of Medicine, as well as on advisory committees for the National Cancer Institute, the National Heart, Lung, and Blood Institute, the National Institute of Environmental Health Sciences and the Council of the National Institute on Aging.While at Duke, Dr. Califf led major initiatives aimed at improving methods and infrastructure for clinical research, including the Clinical Trials Transformation Initiative (CTTI), a public-private partnership co-founded by the FDA and Duke. He also served as the principal investigator for Duke’s Clinical and Translational Science Award and the NIH Health Care Systems Research Collaboratory coordinating center.Dr. Califf is a graduate of Duke University School of Medicine. He completed a residency in internal medicine at the University of California, San Francisco and a fellowship in cardiology at Duke.
Lynda Chin, M.D.
arrow

Lynda Chin, M.D.

Director, Institute for Health Transformation, The University of Texas System
close
info:
Dr. Lynda Chin is the founding Chair of the Department of Genomic Medicine at The University of Texas MD Anderson Cancer Center. She also serves as the Scientific Director of the Institute for Applied Cancer Science at MD Anderson, which merges the best attributes of academia and industry to enable science-driven drug discovery. Dr. Chin is a leader in translational genomic medicine, and her research program spans the fields of transcription, telomere biology, mouse models of human cancer, cancer genomics, and personalized cancer medicine. She holds a number of leadership roles in The Cancer Genome Atlas, a comprehensive effort by the National Institutes of Health to accelerate understanding of the molecular basis of cancer through the use of genomics. Dr. Chin is also a member of the Scientific Steering Committee of the International Cancer Genome Consortium and the Institute of Medicine.For 13 years prior to joining The University of Texas MD Anderson Cancer Center in 2011, Dr. Chin was a professor of Dermatology at Dana-Farber Cancer Institute and Harvard Medical School, and a senior associate member of the Broad Institute of Massachusetts Institute of Technology and Harvard University. She was also the scientific director of the Belfer Institute for Applied Cancer Science. At MD Anderson Cancer Center, Dr. Chin has championed a new model of integration, collaboration and cooperation between research and clinical care enterprises, between academia and industry, to bring to bear the power of technology and patient data on the cancer problem. In particular, she has been the visionary and driver behind MD Anderson’s Oncology Expert Advisor powered by IBM-Watson, and the APOLLO big data platform that supports it. Dr. Chin earned a Doctor of Medicine from Albert Einstein College of Medicine and is a board-certified dermatologist.
Nancy Cox, Ph.D.
arrow

Nancy Cox, Ph.D.

Director, Vanderbilt Genetics Institute; Director, Division of Genetic Medicine; Mary Phillips Edmonds Gray Professor of Genetics
close
info:
Dr. Nancy Cox is a quantitative human geneticist with a long-standing research program in identifying and characterizing the genetic component to common human diseases; current research is focused on large-scale integration of genomic with other “-omics” data as well as biobank and electronic medical records data.
William Crown, Ph.D.
arrow

William Crown, Ph.D.

Chief Scientific Officer, Optum Insight
close
info:
As chief scientific officer, Dr. Crown is responsible for all research activities of OptumLabs. Prior to his current role, Dr. Crown held a number of leadership roles at Optum between 2004 and 2013. Most recently, he was president of the Health Economics and Late Phase Research business unit within Optum — one of the largest global health economics consultancies serving the life sciences sector. Before joining Optum, Dr. Crown was vice president of outcomes research and econometrics at Thompson Reuters Medstat from 1994 to 2004 in the Research and Pharmaceutical division. In that role, he conducted numerous retrospective database analyses of the burden of illness associated with various diseases, particularly respiratory and mental health conditions
Donna R. Cryer, JD
arrow

Donna R. Cryer, JD

President & CEO, Global Liver Institute
close
info:
Donna R. Cryer, JD, has channeled her personal experience as an IBD and liver transplant patient into professional advocacy as president and chief executive officer of the Global Liver Institute.Ms. Cryer brings the patient voice into policy and research deliberations through service to FDA, PCORI, ONC, and NIH. Additionally, Ms. Cryer serves on the Gastroenterology Board of the ABIM, the Personalized Medicine Coalition and is Chair of the Society for Participatory Medicine.Ms. Cryer received an A.B. from Harvard/Radcliffe Colleges and a J.D. from the Georgetown University Law Center.
Andrew Hack
arrow

Andrew Hack

Chief Financial Officer, Editas Medicine
close
info:
Andrew joined Editas Medicine as CFO in July 2015. Previously, he served as a portfolio manager at Millennium Management, where he ran a healthcare fund focused on biotechnology, pharmaceutical and medical device companies from May 2011 to June 2015. Prior to Millennium, Andrew was an analyst at HealthCor Management from December 2008 to May 2011. Prior to HealthCor Management, Andrew was an analyst Carlyle-Blue Wave Partners and a principal of the MPM BioEquities Fund. He started his investment career covering the biotechnology sector at Banc of America Securities. In addition, Andrew was a co-founder of Reify Corporation, a life science tools and drug discovery company. Andrew received his B.A. in biology with special honors from the University of Chicago, where he also received his M.D. and Ph.D., was named the inaugural Frank Family Scholar, and received awards from the American Heart Association and the American Society for Cell Biology.
Jeffrey Hankoff
arrow

Jeffrey Hankoff

Senior Medical Director, Cigna
close
info:
I have been with Cigna for 13 years. I began my Cigna career as Kelly Girl temporary employee medical director and worked my way up to part-time medical director, then full time lead medical director for California, senior medical director, and now Medical Officer. Although officially situated in Glendale, California, I largely work from my home in Santa Barbara, California. My responsibilities include functional oversight nationally of utilization management including precertification, pharmacy, inpatient case management, core case management. In addition, I lead our Genetic Testing initiatives as well as our High Profile Case process and many of our Affordability efforts. Prior to joining Cigna, I was a practicing family physician for over 20 years. I cut my teeth in medical management first as the Chief of Staff at Santa Barbara Cottage Hospital and later as medical director of Santa Barbara Select IPA where I was primarily responsible for utilization management for approximately 25,000 commercial and senior lives. With SBSIPA, I worked closely with two medical management companies – Medical Pathways and later Arcadian. Through Medical Pathways, I also served as medical director for several other medical groups managed by them throughout Southern and Central California. I completed by undergraduate years in Humanities and Science at MIT and my medical school years at the University of California, Davis. I received my family medicine training at Eastern Maine Medical Center in Bangor, Maine. I have lived in Santa Barbara for nearly 35 years. My wife and I have been married for over 37 years. We have two children in their thirties - one an attorney in Los Angeles and the other an economic analyst in Washington, DC. My non-working time is spent taking care of 2 11 year-old Boston Terriers. I fashion myself somewhat of a fitness freak and have completed 7 marathons including consecutive Los Angeles Marathons over a 5 year period. I no longer run but I take long walks with my dogs on a daily basis.
Katherine High, M.D.
arrow

Katherine High, M.D.

Co-Founder, President and Chief Scientific Officer, Spark Therapeutics
close
info:
Dr. Katherine High, a world renowned hematologist, began her career studying the molecular basis of blood coagulation and the development of novel therapeutics for the treatment of bleeding disorders. Her pioneering bench-to-bedside studies of gene therapy for hemophilia led to a series of studies that characterized the human immune response to adeno-associated virus (AAV) vectors in a variety of target tissues. Kathy’s work has evolved to encompass clinical translation of genetic therapies for multiple inherited disorders. As the director of the Center for Cellular and Molecular Therapeutics at The Children’s Hospital of Philadelphia, Kathy assembled a multidisciplinary team of scientists and researchers working to discover new gene and cell therapies for genetic diseases and to facilitate rapid translation of preclinical discoveries into clinical application. Kathy served a five-year term on the FDA Advisory Committee on Cell, Tissue and Gene Therapies and is a past-president of the American Society of Gene & Cell Therapy (ASGCT). She received her A.B. in chemistry from Harvard University, an M.D. from the University of North Carolina School of Medicine, business certification from the UNC Business School Management Institute for Hospital Administrators and a master’s degree from the University of Pennsylvania.
Mark Johnson
arrow

Mark Johnson

Senior Vice President, United Health Group
close
info:
Charles Kennedy, M.D.
arrow

Charles Kennedy, M.D.

Chief Population Health Officer, Healthagen Aetna
close
info:
Charles D. Kennedy, M.D. is chief population health officer for Healthagen. In this role, Dr. Kennedy is responsible for leading Healthagen’s population health and care management strategies and working with health systems and provider organizations to design and implement population health management programs. Previously, Dr. Kennedy was chief executive officer of Accountable Care Solutions from Aetna, a business he helped to establish at Aetna that collaborates with high quality health systems to implement accountable care models.Dr. Kennedy is a recognized expert in health care and health information technology. He was a founding commissioner of the Certification Commission for Health Information Technology (CCHIT), the first organization recognized by the federal government to certify EMRs. He is currently the health insurance industry representative on the HIT Policy Committee, a Federal Advisory Committee that is guiding Centers for Medicare and Medicaid Services (CMS) policies to allocate $40 billion in federal funding for HIT deployment. Dr. Kennedy serves on the AHIP Foundation Board of Directors and on the advisory board for the Center for Healthcare Innovation, Healthcare and Life Science Innovation Lab.Prior to Aetna, Dr. Kennedy was vice president of Health Information Technology for WellPoint Inc. Previously, he served as chief executive officer at CareAssured, which he co-founded, and previously as director of Strategic Informatics at Blue Shield of California. Prior to Blue Shield, Dr. Kennedy served in consulting positions at Electronic Data Systems and its management consulting subsidiary, A.T. Kearney. He was on the medical staff at Kaiser Permanente and other Northern California medical facilities for seven years.Dr. Kennedy holds an M.D. in Internal Medicine from the University of California at Los Angeles, an MBA in Corporate Strategy and Health Care Economics from Stanford University, and a bachelor’s degree in Genetics from the University of California at Berkeley. He has been featured and quoted on the topics of health care technology and operations in news publications and outlets that include ComputerWorld, Bloomberg, Associated Press, The Pink Sheet, The Industry Standard, Modern Healthcare, HealthLeaders and others.
David Ledbetter, Ph.D, FACMG
arrow

David Ledbetter, Ph.D, FACMG

Executive Vice President and Chief Scientific Officer, Geisinger Health System
close
info:
Executive Vice President and Chief Scientific Officer at Geisinger Health System. He came to Geisinger from Atlanta’s Emory University School of Medicine where he was the Robert W. Woodruff Professor and Director of the Division of Medical Genetics in the Department of Human Genetics.
Roger Longman
arrow

Roger Longman

Chief Executive Officer, Real End Points
close
info:
James Lu, M.D., Ph.D.
arrow

James Lu, M.D., Ph.D.

Vice President, Applied Genomics
close
info:
Content
Robert McDonough
arrow

Robert McDonough

Senior Director of Clinical Policy Research and Development, Aetna
close
info:
Christopher Murray
arrow

Christopher Murray

Director, IHME
close
info:
Christopher J.L. Murray, MD, DPhil, is the Director of the Institute for Health Metrics and Evaluation (IHME) and Professor of Global Health at the University of Washington. A physician and health economist, Dr. Murray is widely regarded as one of the founders of modern population health measurement, and his work has helped shape public policy in countries around the world. Dr. Murray created the concept of the Global Burden of Disease with Dr. Alan Lopez while working as a professor at the Harvard School of Public Health. Dr. Murray led the coordination of the Global Burden of Disease Study 2010, the most comprehensive assessment to date of levels and trends in health worldwide. He served as the Executive Director of the World Health Organization’s Evidence and Information for Policy Cluster, where he pioneered the groundbreaking World Health Report 2000, in collaboration with Dr. Julio Frenk. Dr. Murray played a key role in the creation of the 1993 World Development Report, considered a touchstone for all subsequent attempts to study the effects of health policy and health investment on health outcomes. He returned to Harvard to help launch the Harvard Initiative for Global Health (now the Harvard Institute for Global Health) as its first director.Dr. Murray’s work has been cited more than 50,000 times by other researchers in published articles. He holds Bachelor of Arts and Science degrees from Harvard University, a DPhil from Oxford University, and a medical degree from Harvard Medical School.Dr. Murray and Dr. Frenk founded IHME in 2007. By measuring health, tracking program performance, finding ways to maximize health system impact, and developing innovative measurement systems, IHME provides a foundation for informed decision-making that ultimately will lead to better health globally.
John Niederhuber, M.D.
arrow

John Niederhuber, M.D.

CEO, Inova Translational Medicine Institute
close
info:
Dr. Niederhuber brings a lifetime of medical knowledge, large organization management experience and vision to his position as CEO, including his most recent tenure as director of the National Cancer Institute. A nationally renowned surgeon and researcher, he has dedicated his four-decade career to the treatment and study of cancer.Dr. Niederhuber previously served as NCI's chief operating officer and deputy director for translational and clinical sciences and chair of the National Cancer Advisory Board. He remains involved in research at the National Institutes of Health.As a surgeon, Dr. Niederhuber's clinical emphasis is on gastrointestinal cancer, hepatobiliary (liver, bile duct, and gallbladder) and breast cancers. He is recognized for his pioneering work in hepatic artery infusion chemotherapy and was the first to demonstrate the feasibility of totally implantable vascular access devices.Dr. Niederhuber is a member of the Institute of Medicine of the National Academy of Science and has received numerous honors and awards.
Julia Oh, Ph.D.
arrow

Julia Oh, Ph.D.

Assistant Professor, The Jackson LAboratory
close
info:
Dr. Oh's main research interests focus on the human microbiome—the diverse bacteria, fungi, and viruses that inhabit our bodies—for its potential to deliver treatments for infectious and other diseases. Dr. Oh comes to the microbiome world by way of fungal chemogenomics with technologist and geneticist Dr. Ronald Davis at Stanford and comparative genomics of wild wine yeast at the FAS Center for Systems Biology at Harvard. Prior to joining the Jackson Laboratory, she was a postdoctoral fellow at the National Human Genome Research Institute (NHGRI) of the National Institutes of Health. Dr. Oh's research, exploring the complex interactions between the host and its microbes has lead to important implications for the contribution of the microbiome to disease.
Robert Patricelli
arrow

Robert Patricelli

Founder, Chairman and CEO, Women’s Health USA
close
info:
Mr. Patricelli has been a leader in the health care industry for almost 40 years. He is currently the founder, chairman and CEO of Women’s Health USA. He also founded and was CEO successively of Value Health (NYSE) and of Evolution Benefits, and prior to that headed Cigna Corporation’s health care programs including its HMOs in the 1980’s. Previously, Mr. Patricelli held appointments in numerous positions in the federal government, starting as a White House Fellow and serving as Minority Counsel to a U.S. Senate Subcommittee, Deputy Under Secretary for Policy at the Department of Health, Education and Welfare, and as Administrator of the Urban Mass Transportation Administration. He has served on numerous national and local boards of directors, including service of the board and as chair of Curagen Corporation (CRGN). He is a member of the Institute of Medicine and a graduate of Harvard Law School and Wesleyan University.
Michael Pellini, M.D.
arrow

Michael Pellini, M.D.

CEO, Foundation Medicine
close
info:
Michael Pellini is Chief Executive Officer and President at Foundation Medicine, Inc. Dr. Pellini has a breadth of experience in life sciences and the clinical diagnostics and laboratory industries. Previously he was president and chief operating officer at Clarient, a GE Healthcare Company. While at Clarient, he worked with its leadership team to drive critical regulatory and reimbursement strategies in parallel with the development and commercialization of multiple diagnostic tests. Dr. Pellini joined GE Healthcare through the integration of Clarient, Inc., where he was instrumental in building it through the highly successful acquisition by GE Healthcare in October 2010. Dr. Pellini served as Vice President of the Life Sciences Group for Safeguard Scientifics, Inc. until April 2008. From March 2007 to April 2008, at Safeguard Scientifics, he used his business and medical expertise to explore new market opportunities, evaluate the growth potential of prospects and provide support to Safeguard and its partner companies. He served as an Executive officer of Residence of Life Sciences Group of Safeguard Scientifics, Inc. since January 29, 2007. Dr. Pellini served as Chief Operating Officer of PLUS Diagnostics Inc. (formerly, Lakewood Pathology Associates) from April 2005 to December 2006 and also served as its Executive Vice President. He served as President and Chief Executive Officer of Genomics Collaborative, Inc. (GCI) from June 1999 to February 2004. He worked in the investment banking industry in both Philadelphia and Sydney, Australia. Dr. Pellini served as an "Entrepreneur-in-Residence" at BioAdvance from September 2004 to April 2005, where he was responsible for reviewing and evaluating seed stage investment proposals. He worked for several years at Merrill Lynch and led a group of investment managers in Sydney, Australia, establishing a new national standard for asset growth. Dr. Pellini serves as a Director of Safeguard Scientifics Inc., Genomics Collaborative, Inc. and Cira Discovery Sciences, Inc. He served as a Director of Cellumen Inc. since July 2007 and Clarient, Inc. from June 27, 2007 to March 26, 2009. He serves as a Member of Executive Committee of the Board of Trustees of Coriell Institute for Medical Research (The). He serves on the Board of Trustees for the Editorial Board for the journal Biotechnology Healthcare, the Technology Council of Boston College and the Executive Committee for Jefferson Medical College. He trained as a Primary Care Physician in the Thomas Jefferson University Health System. Dr. Pellini holds a Medical Degree from Jefferson Medical College of Thomas Jefferson University, a Master’s in Business Administration Degree from Drexel University and a Bachelor's Degree (B.A.) in Economics from Boston College.
Tomas J. Philipson, Ph.D
arrow

Tomas J. Philipson, Ph.D

Daniel Levin Professor of Public Policy Studies, University of Chicago
close
info:
Dr. Philipson is an economist who holds the Daniel Levin Chair in Public Policy at The University of Chicago and directs The Becker Friedman Institute's health care research program. In addition, he is a co-founder of the health care consulting firm Precision Health Economics, a Visiting Scholar at the American Enterprise Institute, and a Senior Fellow at the Milken Institute. Dr. Philipson has served in the U.S. government as a senior economic adviser to the head of the Food and Drug Administration (FDA), a senior economic adviser to the head of The Centers for Medicaid and Medicare Services (CMS), and a senior health care adviser to Senator John McCain during his 2008 presidential campaign. He received his MA and PhD in economics from The Wharton School and The University of Pennsylvania.
Edward Rubin, M.D., Ph.D.
arrow

Edward Rubin, M.D., Ph.D.

Chief Scientific Officer, Metabiota
close
info:
Content
David Sabow
arrow

David Sabow

Managing Director, Head of Life Science & Healthcare, Silicon Valley Bank
close
info:
David Sabow is a managing director and serves as the head of Silicon Valley Bank’s life science and healthcare practice in the U.S. With more than 15 years of life science and healthcare finance experience, David’s background spans IPOs, follow-on offerings, mergers & acquisitions, senior and subordinated debt, and strategic advisory roles across the life science and healthcare finance sector. David is a frequent speaker at venture capital and life science industry conferences around the world. Recent speaking engagements include the CanceRX meeting at MIT, the BioEnterprise Conference in Cleveland, the Sachs Associates Biotech in Europe Forum in Basel Switzerland, and the Medical Device and Diagnostics Conference in Shanghai. Prior to joining Silicon Valley Bank, David spent almost nine years in the life science investment banking practice at Canaccord Genuity, where he participated in public financings and M&A transactions with an aggregate deal value in excess of $1 billion. While at Canaccord, David worked on both domestic and international transactions across the spectrum of life science and healthcare. Before Canaccord, David worked as a relationship manager with U.S. Bank. David graduated with high distinction from Santa Clara University.
Alan Sachs
arrow

Alan Sachs

Chief Scientific Officer, ThermoFisher
close
info:
Alan Sachs is the Chief Scientific Officer for Thermo Fisher Scientific. He served as the Chief Scientific Officer for Life Technologies/Life Sciences Solutions Group within Thermo Fisher between 2012 and 2015. Prior to this role, Dr. Sachs was the Vice President of Exploratory and Translational Sciences at Merck Research Laboratories. During his ten years at Merck, he built and directed the global RNA Therapeutics Department, led the Rosetta Inpharmatics group, and led the Department of Molecular Profiling. Before joining Merck, Dr. Sachs was an Associate Professor of Molecular and Cell Biology at the University of California at Berkeley, and a Whitehead Institute Fellow at the Whitehead Institute in Cambridge, MA. Dr. Sachs’ academic work focused on understanding of the role of the poly(A) tail in translation and mRNA stability. Dr. Sachs graduated from Cornell University with a B.A. in Biochemistry, received his Ph.D. with Roger Kornberg in Cell Biology at Stanford Medical School, received his M.D. from Stanford Medical School, and completed a post-doctoral fellowship with Ron Davis in the Department of Biochemistry, Stanford Medical School.
Michael Sherman, M.D.
arrow

Michael Sherman, M.D.

Senior Vice President and Chief Medical Officer, Harvard Pilgrim Health Care
close
info:
Dr. Michael Sherman recently joined Harvard Pilgrim Health Care as senior vice president, chief medical officer. For the preceding four years, he served as corporate medical director, physician strategies for Humana, focusing on developing collaborative programs with provider organizations to support their mutual goal of delivering the highest quality care to their patients. Under his direction, Humana implemented a number of Pay for Performance programs as well as a leading edge Medical Home initiative that had over 50,000 members receiving care in affiliated practices and successfully reduced ER and inpatient spend while simultaneously improving the quality of care provided and both physician and member satisfaction. Prior to joining Humana, he held several roles with UnitedHealth Group, including vice president, network and consumer solutions, for Ingenix and also spent time supporting UnitedHealthcare's commercial business. He also served as chief business development officer for United's Medicare Part D business, overseeing its channel partner strategy & execution, including sales to employers, brokers and states. Prior to joining UnitedHealth Group, Dr. Sherman held the position of vice president and general manager at Thomson Medstat (now Thomson Reuters), which provides health information solutions to the payer, provider and research markets. He also served as vice president, business development and product management, for HealthAllies, an organization created to provide discretionary medical benefits to the cash-pay market, which was purchased by UnitedHealth Group in 2003. Dr. Sherman's other roles include stints at Immusol, a San Diego-based biotechnology company, where he served as vice president, medical and clinical affairs and as director, business development, at Total Renal Care (now known as Da Vita), a national provider of dialysis services. Dr. Sherman holds a B.A. degree in Anthropology and Natural Sciences and an M.S. in Biomedical Anthropology from the University of Pennsylvania. He received his M.D. degree from Yale and M.B.A. from the Harvard Business School. Dr. Sherman is a diplomate of both the American Board of Anesthesiology and American Board of Medical Management, and he practiced as a cardiac anesthesiologist prior to pursuing his MBA. In addition, in 2009, he was named a fellow of the American College of Physician Executives in recognition of his national contributions to the field of medical management. Dr. Sherman has been a frequent speaker at national meetings and has been a guest lecturer at the Harvard Business School. He is on the editorial board of the journal, Biotechnology Healthcare, and has served on the Board of Directors of the Hennepin County History Museum.
George Weinstock, Ph.D.
arrow

George Weinstock, Ph.D.

Professor, Director of Microbial Genetics, The Jackson Laboratory
close
info:
Dr. George Weinstock is a Professor and Director of Microbial Genomics at the Jackson Laboratory for Genomic Medicine where he established a group devoted to genomic studies of infectious diseases and the human microbiome. The group collaborates extensively with clinicians to apply genomic analyses to a wide range of medical problems.The goal of the metagenomics projects is to determine the role of the microbiome in health and disease with the aim of providing new diagnostic and therapeutic approaches. His group played a leading role in the NIH Human Microbiome Project including both basic science and clinical studies and his current research follows on those projects. Dr. Weinstock was previously the co-director of the Human Genome Sequencing Center at Baylor College of Medicine in Houston where he was one of the leaders of the Human Genome Project.He has also directed a number of human and mammalian genetics projects aimed at determining genetic causes of conditions such as Retinitis Pigmentosa, Cleft Lip, susceptibility to infection, or the role of host genetics in control of the microbiome.
Frank Witney, Ph.D.
arrow

Frank Witney, Ph.D.

President and CEO, Affymetrix
close
info:
Dr. Frank Witney brings more than 30 years of leadership and innovation in the research, development, and commercialization of many life science products, including diagnostic and analytical instruments to Affymetrix. He previously served at Affymetrix as Executive Vice President and Chief Commercial Officer following the acquisition of Panomics Inc., a quantitative biology company which Dr. Witney had pioneered and served as president and chief executive officer for six years. Prior to returning to Affymetrix, Dr. Witney was President and Chief Executive Officer of Dionex Corporation, an ion and high performance liquid chromatography company which he led to an increase in market share across multiple markets and ultimately a successful acquisition by Thermo Fisher Scientific, Inc.Dr. Witney also served as President and Chief Operating Officer of Packard BioScience, where he oversaw global operations, research and development, manufacturing, and worldwide sales, achieving rapid growth in revenues and operating profits. When Packard was acquired by PerkinElmer Life Sciences, he became President of PerkinElmer’s Drug Discovery Tools division, managing the reagent and instrument business units for high-throughput screening, research products, genomics/proteomics, and liquid handling automation.Earlier in his management career, Dr. Witney held numerous positions at Bio-Rad Laboratories, including Group Operations Manager of the Life Science Group where he led successful efforts to enter rapidly growing markets for proteomics and bioassay technologies.Dr. Witney was a post-doctoral fellow at the National Institutes of Health and holds a doctorate in molecular and cell biology from Indiana University.
Xiaoliang Sunney Xie, Ph.D.
arrow

Xiaoliang Sunney Xie, Ph.D.

Mallinckrodt Professor of Chemistry and Chemical Biology, Harvard University
close
info:
Dr. Xie is considered a founding father of single-molecule enzymology. He was born in Beijing, China in 1962. He received a B.S. in chemistry from Peking University, followed by his Ph.D. in 1990 from the University of California at San Diego. He then conducted his postdoctoral research at the University of Chicago. In 1992, Xie joined Pacific Northwest National Laboratory, where he promoted to Chief Scientist. In 1999, he was appointed Professor of Chemistry and Chemical Biology at Harvard University. He is now the Mallinckrodt Professor of Chemistry and Chemical Biology at Harvard University, and the Cheung Kong Visiting Professor and Director of Biodynamics Optical Imaging Center (BIOPIC) at Peking University.Among the first to conduct fluorescence studies of single molecules at room temperature in the early 1990s, he has made significant contributions to the emergence of single-molecule biology, generating excitement in the life sciences community. His work focuses on single-molecule enzymology, gene expression dynamics, and, most recently,single cell genomics.In particular, the fluorescence work underpinned his real-time observation of enzymes mediating catalytic reactions (turnovers) one reaction at a time. The investigation fundamentally changed researchers’ understanding of enzyme dynamics by showing that single-enzyme rate constants fluctuate in time due to conformation changes.Such fluctuations have since been observed in many systems. Yet the Michaelis-Menten equation still holds at the single-enzyme level.His group made advances with their real-time observation of protein production in a living cell, one molecule at a time. That work provided a fundamental description to quantify gene expression and revealed the molecular level mechanisms in live cells. His team also proved that individual molecules’ stochastic events can alter a cell’s phenotype, demonstrating the biological importance of single-molecule studies.Recently Xie and coworkers invented a single cell whole genome amplification method, allowing nearly an entire genome of a single cell to be sequenced with the detectability of a single point mutation. With the aid of this method, two babies were born in 2014 via in vitro fertilization, free from their parents’ genetic diseases associated with point mutations.Xie’s team also pioneered coherent Raman scattering microscopy, an imaging technique that does not rely on fluorophores, but on vibrational contrast with molecular selectivity. These methods generate a label free chemical map of cells, providing a new imaging tool for cellular biochemistry and medical diagnosis.Xie has served on the editorial boards of numerous journals including Science, Annual Review of Physical Chemistry, and Accounts of Chemical Research. He has organized numerous scientific conferences, including several single-molecule symposia and a Gordon conference on the single-molecule approach to biology that he cofounded.He is a member of the National Academy of Sciences and a fellow of various organizations, including the American Physical Society, the American Academy of Arts & Sciences, the American Association for the Advancement of Science, the Biophysical Society, Optical Society of America, and the American Academy of Microbiology.Among other accolades, Xie has been honored with the U. S. Department of Energy E. O. Lawrence Award, the Biophysical Society’s Founders Award, and the National Institute of Health Director’s Pioneer Award, and American Chemical Society’s Peter DebyeAward. He is also an honorary fellow of the Chinese Chemical Society and has received scholarly awards from Germany and Israel.